





Polymyxin B (injection)



Statut de médicament essentiel ✓

Section: 6. Anti-infective medicines > 6.2. Antibacterials > 6.2.3. Reserve group antibiotics

		EMLc	Codes ATC: J01XB02
Indication	Carbapenem resistant Acinetobacter baumannii	Code ICD11: MG50.02	
INN	Polymyxin B		
Type de médicament	Chemical agent		
Groupes d'antibiotiques	 RESERVE		
Type de liste	Liste complémentaire (EML) (EMLc)		
Formulations	Parenteral > General injections > IV: 500000 IU in vial powder for injection (equivalent to 50 mg polymyxin B base)		
Historique des statuts LME	Ajouté pour la première fois en 2019 (TRS 1021) Modifié en 2023 (TRS 1049)		
Sexe	Tous		
Âge	Aussi recommandé pour les enfants		
Équivalence thérapeutique	La recommandation concerne ce médicament spécifique		
Renseignements sur le brevet	Patents have expired in most jurisdictions Lire la suite sur les brevets. 		
Wikipédia	Polymyxin B (injection) 		
DrugBank	Polymyxin b (Polymyxin B Sulfate) 		

Résumé des preuves et recommandation du comité d'experts

In consideration of the review of the age appropriateness of formulations of medicines on the EMLc, and the comparison report of the EML versus EMLc, the Expert Committee recommended changes to the EMLc for addition of new, age-appropriate formulations and strengths of existing essential medicines, deletion of unavailable or age-inappropriate formulations and strengths, and other listing modifications as proposed in the application. The Committee also endorsed the proposals for further review of the public health relevance and evidence for specific medicines for use in children for potential future consideration for inclusion on the EMLc. The Committee noted and welcomed the ongoing review being coordinated by the Secretariat for the remaining sections of the EMLc for consideration by the 2025 Expert Committee. As a result of the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended the listing for polymyxin B on the EML and EMLc be amended to include also the equivalent strength in mg of polymyxin B base.

